Great #AHA23 so far: @AHA_Research
🥸8 Trials: 8 take aways below
Read the read👇👇
1/ATRESIA:
Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.
🥸8 Trials: 8 take aways below
Read the read👇👇
1/ATRESIA:
Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.
3/ CRHCP:
🥸Intensive BP lowering (target BP < 130/80 mm Hg) significantly reduced risk of all-cause dementia among patients with hypertension, supporting the use of intensive hypertension treatment to reduce the burden of dementia.
😱 @cardskrish
🥸Intensive BP lowering (target BP < 130/80 mm Hg) significantly reduced risk of all-cause dementia among patients with hypertension, supporting the use of intensive hypertension treatment to reduce the burden of dementia.
😱 @cardskrish
6/ORBITA-2
PCI outperformed a placebo procedure for people with minimal anti-anginal medication enhancing chest pain relief, exercise ability, and overall quality of life!
😱PCI works: @JAMAInternalMed
PCI outperformed a placebo procedure for people with minimal anti-anginal medication enhancing chest pain relief, exercise ability, and overall quality of life!
😱PCI works: @JAMAInternalMed
** Sorry for typo: meant "read the thread"
9/Heart-1
🥸 Single course gene editing medicine could emerge as a game changer in treating elevated LDL-levels.
#VERVTherapeutics
🥸 Single course gene editing medicine could emerge as a game changer in treating elevated LDL-levels.
#VERVTherapeutics
Loading suggestions...